Recent Updates
Recently added Catalysts
PETS Positive Sentiment

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: PetMeds has announced equity awards for two newly hired executives as part of its inducement strategy under Nasdaq Listing Rule 5635(c)(4). CEO Jeff Willard received 250,000 shares of restricted stock and performance share units, while CTO Andrew Parry was granted 100,000 shares. The awards are designed to incentivize long-term performance and retention.

Market Sentiment Analysis

POSITIVE FACTORS

  • PetMeds is attracting top talent with significant equity awards.
  • The inducement grants are aligned with the company's growth strategy.
  • The performance share units offer potential for long-term shareholder value.

Full Press Release Details

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.
On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units (“PSUs”), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock.
The awards were granted pursuant to PetMeds’ 2024 Inducement Incentive Plan, as amended and restated, which was adopted by the Board of Directors in September 2024 and amended in September 2026. The restricted stock awards will vest over three years in equal one-third increments on each of the first three (3) anniversaries of the grant date, subject to continued employment with the Company on each vesting date. The PSUs granted to Mr. Willard each represent a contingent right to receive one share of the Company's common stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029. The awards were granted as a material inducement to employment with PetMeds, in accordance with Nasdaq Listing Rule 5635(c)(4).

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Investor Contact ICR, LLC Reed Anderson investor@petmeds.com

Frequently Asked Questions

What are the inducement grants announced by PetMeds?

PetMeds announced equity awards for two new executives as inducements for employment.

Who received the equity awards from PetMeds?

Jeff Willard, CEO, received 250,000 shares and Andrew Parry, CTO, received 100,000 shares.

What is the vesting schedule for the restricted stock?

The restricted stock will vest over three years in equal one-third increments.

What do the performance share units represent?

The PSUs represent a right to receive shares based on achieving performance targets.

Last updated: Oct 2, 2026